Histogenics Corp. (NASDAQ:HSGX) shot up 30.2% during mid-day trading on Monday . The company traded as high as $2.97 and last traded at $2.76, with a volume of 58,985 shares trading hands. The stock had previously closed at $2.12.

A number of research firms have recently issued reports on HSGX. Canaccord Genuity restated a “buy” rating on shares of Histogenics Corp. in a report on Thursday, May 12th. BTIG Research upgraded shares of Histogenics Corp. from a “neutral” rating to a “buy” rating and set a $3.50 price target on the stock in a report on Thursday, August 11th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Histogenics Corp. presently has an average rating of “Buy” and an average price target of $9.75.

The firm’s 50-day moving average is $1.99 and its 200-day moving average is $2.19. The company’s market cap is $48.98 million.

Histogenics Corp. (NASDAQ:HSGX) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.60) by $0.01. During the same quarter in the previous year, the business posted ($0.58) EPS. Equities research analysts expect that Histogenics Corp. will post ($2.09) earnings per share for the current year.

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.